InnoCare Pharma HK$3.04 billion share placement
We advised InnoCare Pharma in the placement of new shares
Experience
To find Davis Polk deals and cases of particular interest, select filters based on practice, industry, region, lawyer and keyword.
Filters
New Horizon Health HK$2.04 billion IPO
We advised New Horizon Health on its IPO and HKEX listing
Akeso HK$1.19 billion share placement
We advised the placing agent in the placement of new shares
Corvus Pharmaceuticals $34 million stock offering
We advised the underwriters on the equity offering
Biogen exchange offer
We advised the dealer managers on a debt exchange offer
Oak Street Health $600.5 million secondary offering
We advised the joint book-running managers on the equity offering
Signify Health $648.6 million IPO
We advised Signify Health on its IPO and NYSE listing
Adagene $161 million IPO
We advised Adagene on its IPO and Nasdaq listing
Bolt Biotherapeutics $230 million IPO
We advised the underwriters on the IPO and Nasdaq listing
Immunocore $297 million IPO
We advised the joint book-running managers and underwriters on the IPO and Nasdaq listing